News Focus
News Focus
Followers 33
Posts 4311
Boards Moderated 0
Alias Born 07/16/2014

Re: KMBJN post# 146686

Friday, 05/06/2016 8:04:11 AM

Friday, May 06, 2016 8:04:11 AM

Post# of 405194
The points you make are absolutely why Leo has termed this Cellceutix's "riskiest drug trial". I am stuck on Mobil so these figures (in the patent) don't show up for me, but it sort of points to other MOA's that might be behind possible effectiveness. Perhaps it shouldn't, but the relative effectiveness to Methotrexate in the exact mouse model gives me a bit more confidence.
The little ball is in motion and it will either be red or black. I have my chips on black!

"Figure 1 shows production of IL-20 in mice by Prurisol (at doses of 10 mg/kg or 2 x 10 mg/kg ) and MTX (methotrexate) (at dose 7.5 mg/kg).

Figure 2 shows supression of psoriasis susceptibility related RNA gene induced by stress (PRINS) after administering Prurisol (at doses of 10 mg/kg or 2 x 10 mg/kg) and MTX (7.5 m/kg).

Figure 3 shows appearance of skin after administration of Prurisol and MTX.

Figure 4 shows Normalization of skin in histological parameters compare to fully psoriatic skin and MTX.

Figure 5 shows induction of 12-R lipoxygenase activity by Prurisol and MTX.

Figure 6 shows appearance of skin by naked eye in psoriatic animals and those treated with Prurisol.

Figure 7 shows reduction of CD4.

Figure 8 shows reduction of CD8.

http://www.google.com/patents/WO2013103601A1?cl=en


LEGEND OF ABBREVIATIONS
B = Brilacidin, the antibiotic
K = Kevetrin, the oncology drug
P = Prurisol, the psoriasis drug
SAE = Serious Adverse Event
IND = Investigational New Drug


Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y